CoChat

Clinical update on K-Ras targeted therapy in gastrointestinal cancers

Pant, Shubham, Hubbard, Joleen, Martinelli, Erika, Bekaii-Saab, Tanios · 2018 · Critical Reviews in Oncology/Hematology
Cited by 18

The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.critrevonc.2018.07.011

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 47 references

Research works printed but not linked: 125

  1. Abdul Razak, 2016, First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors, J. Clin. Oncol., 34, 4142, 10.1200/JCO.2015.65.3949 · DOI · Paper page
  2. Adair, 2012, Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients, Sci. Transl. Med., 4, 138ra77, 10.1126/scitranslmed.3003578 · DOI · Paper page
  3. Adjei, 2008, Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers, J. Clin. Oncol., 26, 2139, 10.1200/JCO.2007.14.4956 · DOI · Paper page
  4. Akinleye, 2015, Novel agents for advanced pancreatic cancer, Oncotarget, 6, 39521, 10.18632/oncotarget.3999 · DOI
  5. Allegra, 2016, Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015, J. Clin. Oncol., 34, 179, 10.1200/JCO.2015.63.9674 · DOI · Paper page
  6. Andrews, 2013, BRAF inhibitor-driven tumor proliferation in a KRAS-mutated colon carcinoma is not overcome by MEK1/2 inhibition, J. Clin. Oncol., 31, e448, 10.1200/JCO.2013.50.4118 · DOI
  7. Athuluri-Divakar, 2016, A small molecule RAS-Mimetic disrupts RAS association with effector proteins to block signaling, Cell, 165, 643, 10.1016/j.cell.2016.03.045 · DOI · Paper page
  8. Bedard, 2015, A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors, Clin. Cancer Res., 21, 730, 10.1158/1078-0432.CCR-14-1814 · DOI · Paper page
  9. Bendell, 2011, Abstract B243: a phase I dose-escalation study of MEK inhibitor MEK162 (ARRY-438162) in patients with advanced solid tumors, Mol. Cancer Ther., 10, B243, 10.1158/1535-7163.TARG-11-B243 · DOI
  10. Bendell, 2018, A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC), J. Clin. Oncol., 36
  11. Benson, 2017, Colon Cancer, version 1.2017, NCCN clinical practice guidelines in oncology, J. Compr. Canc. Netw., 370, 10.6004/jnccn.2017.0036 · DOI · Paper page
  12. Blake, 2016, Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-y l)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor in early clinical development, J. Med. Chem., 59, 5650, 10.1021/acs.jmedchem.6b00389 · DOI · Paper page
  13. Bournet, 2016, Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: hopes and realities, Eur. J. Cancer, 54, 75, 10.1016/j.ejca.2015.11.012 · DOI · Paper page
  14. Brown, 2017, Maximising the potential of AKT inhibitors as anti-cancer treatments, Pharmacol. Ther., 172, 101, 10.1016/j.pharmthera.2016.12.001 · DOI · Paper page
  15. Buck, 2008, Feedback mechanisms promote cooperativity for small molecule inhibitors of epidermal and insulin-like growth factor receptors, Cancer Res., 68, 8322, 10.1158/0008-5472.CAN-07-6720 · DOI · Paper page
  16. Callahan, 2012, Progression of RAS-mutant leukemia during RAF inhibitor treatment, N. Engl. J. Med., 367, 2316, 10.1056/NEJMoa1208958 · DOI · Paper page
  17. Carlino, 2015, New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma, J. Clin. Oncol., 33, e52, 10.1200/JCO.2013.51.5783 · DOI
  18. Casar, 2016, ERK Signals: Scaffolding Scaffolds?, Front. Cell Dev. Biol., 4, 49, 10.3389/fcell.2016.00049 · DOI
  19. Chu, 2016, Regulation of oncogenic KRAS signaling via a novel KRAS-integrin-linked kinase-hnRNPA1 regulatory loop in human pancreatic cancer cells, Oncogene, 35, 3897, 10.1038/onc.2015.458 · DOI
  20. Coeshott, 2014, Abstract A28: immune responses to mutated Ras - development of a yeast-based immunotherapeutic, Mol. Cancer Res., 12, 10.1158/1557-3125.RASONC14-A28 · DOI
  21. Day, 2013, PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer, Clin. Cancer Res., 19, 3285, 10.1158/1078-0432.CCR-12-3614 · DOI · Paper page
  22. de la Chapelle, 2010, Clinical relevance of microsatellite instability in colorectal cancer, J. Clin. Oncol., 28, 3380, 10.1200/JCO.2009.27.0652 · DOI · Paper page
  23. De Roock, 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, Lancet Oncol., 11, 753, 10.1016/S1470-2045(10)70130-3 · DOI · Paper page
  24. Delaney, 2017, Abstract 3015: selective inhibition of mutant KRAS cell and tumor growth by PHT-7.3, an inhibitor of the KRas signaling nanocluster protein Cnk1, Cancer Res., 77, 3015, 10.1158/1538-7445.AM2017-3015 · doi:10.1158/1538-7445.am2017-3015
  25. Delord, 2010, First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors, J. Clin. Oncol., 28, 10.1200/jco.2010.28.15_suppl.2504 · DOI
  26. Desai, 2016, Phase I study of RAF dimer inhibitor BGB-283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors, Cancer Res., 76
  27. Desai, 2017, A phase IB study of RAF dimer inhibitor BGB -283 in patients with B-RAF or K-RAS/N-RAS mutated solid tumors, Cancer Res., 77
  28. Dhawan, 2016, Small molecule stabilization of the KSR inactive state antagonizes oncogenic Ras signalling, Nature, 537, 112, 10.1038/nature19327 · DOI · Paper page
  29. Di Nicolantonio, 2010, Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus, J. Clin. Invest., 120, 2858, 10.1172/JCI37539 · DOI · Paper page
  30. Dickson, 2015, Phase I study of XL281 (BMS-908662), a potent oral RAF kinase inhibitor, in patients with advanced solid tumors, Invest. New Drugs, 33, 349, 10.1007/s10637-014-0191-5 · DOI
  31. Do, 2015, Biomarker-driven phase 2 study of MK-2206 and selumetinib (AZD6244, ARRY-142886) in patients with colorectal cancer, Invest. New Drugs, 33, 720, 10.1007/s10637-015-0212-z · DOI · Paper page
  32. Ducreux, 2015, Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 26, v56, 10.1093/annonc/mdv295 · DOI · Paper page
  33. Eriksen, 2017, An observational clinical study with RAS peptide vaccine TG01 evaluating immune response, safety and overall survival in patients with non-resectable pancreatic cancer, Ann. Oncol., 28, 10.1093/annonc/mdx376.018 · DOI
  34. Etoh, 2003, Oncolytic viral therapy for human pancreatic cancer cells by reovirus, Clin. Cancer Res., 9, 1218
  35. Fernandez-Medarde, 2011, Ras in cancer and developmental diseases, Genes Cancer, 2, 344, 10.1177/1947601911411084 · DOI · Paper page
  36. Ganesan, 2013, Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations, Mol. Cancer Ther., 12, 2857, 10.1158/1535-7163.MCT-13-0319-T · DOI · Paper page
  37. Gonsalves, 2014, Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147, J. Natl. Cancer Inst., 106, 10.1093/jnci/dju106 · DOI · Paper page
  38. Graham, 2016, Molecular subtypes and personalized therapy in metastatic colorectal Cancer, Curr. Colorectal Cancer Rep., 12, 141, 10.1007/s11888-016-0312-y · DOI
  39. Harris, 2016, Updated efficacy and safety results from the phase I study of intermittent dosing of the dual MEK/RAF inhibitor, RO5126766 in patients (pts) with RAS/RAF mutated advanced solid tumours, J. Clin. Oncol., 34, abstr 2582, 10.1200/JCO.2016.34.15_suppl.2582 · DOI
  40. Hatzivassiliou, 2010, RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth, Nature, 464, 431, 10.1038/nature08833 · DOI · Paper page
  41. Hayes, 2016, Long-term ERK inhibition in KRAS-Mutant pancreatic Cancer is associated with MYC degradation and senescence-like growth suppression, Cancer Cell, 29, 75, 10.1016/j.ccell.2015.11.011 · DOI · Paper page
  42. Heestand, 2015, Molecular landscape of pancreatic cancer: implications for current clinical trials, Oncotarget, 6, 4553, 10.18632/oncotarget.2972 · DOI
  43. Heidorn, 2010, Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF, Cell, 140, 209, 10.1016/j.cell.2009.12.040 · DOI · Paper page
  44. Heist, 2014, Pimasertib (PIM) and SAR245409 (SAR) - a MEK and PI3K/MTOR inhibitor combination: a phase IB trial with expansions in selected genotype-defined solid tumors, Ann. Oncol., 25, iv146, 10.1093/annonc/mdu331.3 · DOI
  45. Herrero, 2015, Small molecule inhibition of ERK dimerization prevents tumorigenesis by RAS-ERK pathway oncogenes, Cancer Cell, 28, 170, 10.1016/j.ccell.2015.07.001 · DOI
  46. Hochster, 2015, Phase II study of selumetinib (AZD6244, ARRY-142886) plus irinotecan as second-line therapy in patients with K-RAS mutated colorectal cancer, Cancer Chemother. Pharmacol., 75, 17, 10.1007/s00280-014-2609-3 · DOI
  47. Hong, 2016, First-in-human study of HM95573, a novel oral RAF inhibitor, in patients with solid tumors, J. Clin. Oncol., 34, 2570, 10.1200/JCO.2016.34.15_suppl.2570 · doi:10.1200/jco.2016.34.15_suppl.2570
  48. Huang, 2009, Prognostic value of CRM1 in pancreas cancer, Clin. Invest. Med., 32, E315, 10.25011/cim.v32i6.10668 · DOI · Paper page
  49. Ihle, 2009, Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance, Cancer Res., 69, 143, 10.1158/0008-5472.CAN-07-6656 · DOI · Paper page
  50. Infante, 2014, A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreas, Eur. J. Cancer, 50, 2072, 10.1016/j.ejca.2014.04.024 · DOI · Paper page
  51. Jameson, 2013, IQGAP1 scaffold-kinase interaction blockade selectively targets RAS-MAP kinase-driven tumors, Nat. Med., 19, 626, 10.1038/nm.3165 · DOI · Paper page
  52. Janku, 2011, PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors, Mol. Cancer Ther., 10, 558, 10.1158/1535-7163.MCT-10-0994 · DOI · Paper page
  53. Janku, 2013, PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials, Cancer Res., 73, 276, 10.1158/0008-5472.CAN-12-1726 · DOI · Paper page
  54. Juric, 2014, A phase 1b dose-escalation study of BYL719 plus binimetinib (MEK162) in patients with selected advanced solid tumors, J. Clin. Oncol., 32, 9051, 10.1200/jco.2014.32.15_suppl.9051 · DOI · Paper page
  55. Kamerkar, 2017, Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer, Nature, 546, 498, 10.1038/nature22341 · DOI · Paper page
  56. Kazim, 2015, Selective nuclear export inhibitor KPT-330 enhances the antitumor activity of gemcitabine in human pancreatic Cancer, Mol. Cancer Ther., 14, 1570, 10.1158/1535-7163.MCT-15-0104 · DOI
  57. Kim, 2013, Coexistent mutations of KRAS and PIK3CA affect the efficacy of NVP-BEZ235, a dual PI3K/MTOR inhibitor, in regulating the PI3K/MTOR pathway in colorectal cancer, Int. J. Cancer, 133, 984, 10.1002/ijc.28073 · DOI
  58. Kim, 2016, The inositide signaling pathway As a target for treating gastric Cancer and colorectal Cancer, Front. Physiol., 7, 168, 10.3389/fphys.2016.00168 · DOI
  59. Kimmelman, 2015, Metabolic dependencies in RAS-Driven cancers, Clin. Cancer Res., 21, 1828, 10.1158/1078-0432.CCR-14-2425 · DOI · Paper page
  60. Knickelbein, 2015, Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer, Genes Dis., 2, 4, 10.1016/j.gendis.2014.10.002 · DOI · Paper page
  61. Ko, 2016, A multicenter, open-label phase II clinical trial of combined MEK plus EGFR inhibition for chemotherapy-refractory advanced pancreatic adenocarcinoma, Clin. Cancer Res., 22, 61, 10.1158/1078-0432.CCR-15-0979 · DOI · Paper page
  62. Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596 · DOI · Paper page
  63. Lee, 2011, Identification and characterization of a novel integrin-linked kinase inhibitor, J. Med. Chem., 54, 6364, 10.1021/jm2007744 · DOI · Paper page
  64. Lievre, 2006, KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res., 66, 3992, 10.1158/0008-5472.CAN-06-0191 · DOI · Paper page
  65. Lim, 2016, Discovery of 1-(1H-Pyrazolo[4,3-c]pyridin-6-yl)urea Inhibitors of Extracellular Signal-Regulated Kinase (ERK) for the Treatment of Cancers, J. Med. Chem., 59, 6501, 10.1021/acs.jmedchem.6b00708 · DOI
  66. Lin, 2016, The Hippo effector YAP regulates the response of cancer cells to MAPK pathway inhibitors, Mol. Cell Oncol., 3, e1021441, 10.1080/23723556.2015.1021441 · DOI
  67. LoRusso, 2012, A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors, J. Clin. Oncol., 30, 2566, 10.1200/jco.2012.30.15_suppl.2566 · DOI · Paper page
  68. Macarulla, 2015, Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer, Br. J. Cancer, 112, 1874, 10.1038/bjc.2015.144 · DOI · Paper page
  69. Mahalingam, 2015, Oncolytic virus therapy in pancreatic cancer: clinical efficacy and pharmacodynamic analysis of REOLYSIN in combination with gemcitabine in patients with advanced pancreatic adenocarcinom, Ann. Oncol., 26, iv51, 10.1093/annonc/mdv233.175 · doi:10.1093/annonc/mdv233.175
  70. Mahalingam, 2017, A study of REOLYSIN in combination with pembrolizumab and chemotherapy in patients (pts) with relapsed metastatic adenocarcinoma of the pancreas (MAP), J. Clin. Oncol., 35, 10.1200/JCO.2017.35.15_suppl.e15753 · DOI
  71. Mann, 2016, KRAS-related proteins in pancreatic cancer, Pharmacol. Ther., 168, 29, 10.1016/j.pharmthera.2016.09.003 · DOI · Paper page
  72. Martinez-Garcia, 2012, First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors, Clin. Cancer Res., 18, 4806, 10.1158/1078-0432.CCR-12-0742 · DOI · Paper page
  73. Martin-Gago, 2017, Structure-based development of PDEdelta inhibitors, Biol. Chem., 398, 535, 10.1515/hsz-2016-0272 · DOI · Paper page
  74. Matsunaga, 2014, IQGAP1 selectively interacts with K-Ras but not with H-Ras and modulates K-Ras function, Biochem. Biophys. Res. Commun., 444, 360, 10.1016/j.bbrc.2014.01.041 · DOI
  75. McDonald, 2008, Integrin-linked kinase--essential roles in physiology and cancer biology, J. Cell. Sci., 121, 3121, 10.1242/jcs.017996 · DOI · Paper page
  76. Middleton, 2014, 364 first-in-human phase 1 study of MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors, including BRAF/NRAS-mutant melanoma, Eur. J. Cancer, 50, 117, 10.1016/S0959-8049(14)70490-3 · doi:10.1016/s0959-8049(14)70490-3
  77. Namgoong, 2016, A selective and potent pan-RAF inhibitor, HM95573 exhibits high therapeutic potential as a next-generation RAF inhibitor by direct inhibition of RAF kinase activity in BRAF or RAS mutant cancers, Eur. J. Cancer, 69, S127, 10.1016/S0959-8049(16)32979-3 · doi:10.1016/s0959-8049(16)32979-3
  78. Ning, 2017, Targeting ERK enhances the cytotoxic effect of the novel PI3K and mTOR dual inhibitor VS-5584 in preclinical models of pancreatic cancer, Oncotarget, 8, 44295, 10.18632/oncotarget.17869 · DOI
  79. O’Neil, 2015, A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer, Ann. Oncol., 26, 1923, 10.1093/annonc/mdv264 · DOI
  80. Oberholzer, 2012, RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors, J. Clin. Oncol., 30, 316, 10.1200/JCO.2011.36.7680 · DOI · Paper page
  81. Ocean, 2013, A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS-mutant metastatic colorectal cancer (mCRC), J. Clin. Oncol., 31
  82. Ogino, 2009, PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer, J. Clin. Oncol., 27, 1477, 10.1200/JCO.2008.18.6544 · DOI · Paper page
  83. Overman, 2017, Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study, Lancet Oncol., 18, 1182, 10.1016/S1470-2045(17)30422-9 · DOI · Paper page
  84. Papke, 2016, Identification of pyrazolopyridazinones as PDEdelta inhibitors, Nat. Commun., 7, 11360, 10.1038/ncomms11360 · DOI · Paper page
  85. Parker, 2015, The ras-membrane interface: isoform-specific differences in the catalytic domain, Mol. Cancer Res., 13, 595, 10.1158/1541-7786.MCR-14-0535 · DOI · Paper page
  86. Pecot, 2014, Therapeutic silencing of KRAS using systemically delivered siRNAs, Mol. Cancer Ther., 13, 2876, 10.1158/1535-7163.MCT-14-0074 · DOI · Paper page
  87. Poulikakos, 2010, RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF, Nature, 464, 427, 10.1038/nature08902 · DOI · Paper page
  88. Rajani, 2016, Combination therapy with reovirus and Anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses, Mol. Ther., 24, 166, 10.1038/mt.2015.156 · DOI · Paper page
  89. Rasco, 2013, MLN2480, an investigational oral pan-RAF kinase inhibitor, in patients (pts) with relapsed or refractory solid tumors: phase I study, J. Clin. Oncol., 31, 10.1200/jco.2013.31.15_suppl.2547 · doi:10.1200/jco.2013.31.15_suppl.2547
  90. Revenko, 2013, Characterization of next generation (Gen2.5) KRAS antisense inhibitors in NSCLC, PDAC, and CRC models, Mol. Cancer Ther., 12, A259, 10.1158/1535-7163.TARG-13-A259 · DOI
  91. Richards, 2012, A phase 2 adjuvant trial of GI-4000 plus gemcitabine vs. Gemcitabine alone in RAS+ patients with resected pancreas cancer: R1 subgroup analysis, Ann. Oncol., 23, iv5, 10.1016/S0923-7534(19)66467-7 · DOI
  92. Sahin, 2013, Rare though not mutually exclusive: a report of three cases of concomitant KRAS and BRAF mutation and a review of the literature, J. Cancer, 4, 320, 10.7150/jca.3619 · DOI · Paper page
  93. Sartore-Bianchi, 2016, Challenging chemoresistant metastatic colorectal cancer: therapeutic strategies from the clinic and from the laboratory, Ann. Oncol., 27, 1456, 10.1093/annonc/mdw191 · DOI
  94. Sawai, 2006, Integrin-linked kinase activity is associated with interleukin-1 alpha-induced progressive behavior of pancreatic cancer and poor patient survival, Oncogene, 25, 3237, 10.1038/sj.onc.1209356 · DOI
  95. Seguin, 2017, Galectin-3, a druggable vulnerability for KRAS-Addicted cancers, Cancer Discov., 7, 1464, 10.1158/2159-8290.CD-17-0539 · DOI · Paper page
  96. Seow, 2016, Advances in targeted and immunobased therapies for colorectal cancer in the genomic era, Onco. Ther., 9, 1899, 10.2147/OTT.S95101 · DOI
  97. Shin, 2017, Antibody targeting intracellular oncogenic Ras mutants exerts anti-tumour effects after systemic administration, Nat. Commun., 8, 15090, 10.1038/ncomms15090 · DOI
  98. Singh, 2015, Immune checkpoints and immunotherapy for colorectal cancer, Gastroenterol. Rep. (Oxf)., 3, 289
  99. Smakman, 2005, Sensitization to apoptosis underlies KrasD12-dependent oncolysis of murine C26 colorectal carcinoma cells by reovirus T3D, J. Virol., 79, 14981, 10.1128/JVI.79.23.14981-14985.2005 · doi:10.1128/jvi.79.23.14981-14985.2005
  100. Smakman, 2006, Immunosuppression promotes reovirus therapy of colorectal liver metastases, Cancer Gene Ther., 13, 815, 10.1038/sj.cgt.7700949 · DOI
  101. Strand, 2016, Precision cancer therapy through nanoparticle delivery of siRNA against KRAS, J. Clin. Oncol., 34
  102. Strong, 1998, The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus, EMBO J., 17, 3351, 10.1093/emboj/17.12.3351 · DOI · Paper page
  103. Sullivan, 2018, First-in-Class ERK1/2 inhibitor ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study, Cancer Discov., 8, 184, 10.1158/2159-8290.CD-17-1119 · DOI · Paper page
  104. Tabernero, 2013, First-in-humans trial of an RNA interference therapeutic targeting VEGF and KSP in cancer patients with liver involvement, Cancer Discov., 3, 406, 10.1158/2159-8290.CD-12-0429 · DOI · Paper page
  105. Tan, 2013, Bcl-2/Bcl-xL inhibition increases the efficacy of MEK inhibition alone and in combination with PI3 kinase inhibition in lung and pancreatic tumor models, Mol. Cancer Ther., 12, 853, 10.1158/1535-7163.MCT-12-0949 · DOI · Paper page
  106. Tang, 2016, A randomized phase 2 trial of FOLFOX6/bevacizumab with or without reovirus (Reo) in patients (pts) with metastatic colorectal cancer (mCRC), J. Clin. Oncol., 34
  107. Tape, 2016, Oncogenic KRAS regulates tumor cell signaling via stromal reciprocation, Cell, 165, 910, 10.1016/j.cell.2016.03.029 · DOI · Paper page
  108. Thind, 2017, Immunotherapy in pancreatic cancer treatment: a new frontier, Therap. Adv. Gastroenterol., 10, 168, 10.1177/1756283X16667909 · DOI
  109. Tian, 2017, Development of direct inhibitors of KRAS mutants for the treatment of cancer, Cancer Res., 77, 3237, 10.1158/1538-7445.AM2017-3237 · DOI
  110. Tolcher, 2015, Antitumor activity in RAS-driven tumors by blocking AKT and MEK, Clin. Cancer Res., 21, 739, 10.1158/1078-0432.CCR-14-1901 · DOI · Paper page
  111. Tsang, 2017, U1 adaptors suppress the KRAS-MYC oncogenic Axis in human pancreatic Cancer xenografts, Mol. Cancer Ther., 16, 1445, 10.1158/1535-7163.MCT-16-0867 · DOI
  112. Turner, 2012, Nuclear export of proteins and drug resistance in cancer, Biochem. Pharmacol., 83, 1021, 10.1016/j.bcp.2011.12.016 · DOI · Paper page
  113. Vakana, 2017, LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer, Oncotarget, 8, 9251, 10.18632/oncotarget.14002 · DOI · Paper page
  114. Van Cutsem, 2018, Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer, Int. J. Cancer, 10.1002/ijc.31603 · DOI · Paper page
  115. Varga, 2016, A first-in-human phase I study to evaluate the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors, Eur. J. Cancer, 69, S11, 10.1016/S0959-8049(16)32624-7 · DOI
  116. Weden, 2011, Long-term follow-up of patients with resected pancreatic cancer following vaccination against mutant K-ras, Int. J. Cancer, 128, 1120, 10.1002/ijc.25449 · DOI · Paper page
  117. Weekes, 2017, A Phase Ib study to evaluate the MEK inhibitor cobimetinib in combination with the ERK1/2 inhibitor GDC-0994 in patients with advanced solid tumors, Cancer Res., 77, CT107, 10.1158/1538-7445.AM2017-CT107 · DOI
  118. Welsch, 2017, Multivalent small-molecule Pan-RAS inhibitors, Cell, 168, 878, 10.1016/j.cell.2017.02.006 · DOI · Paper page
  119. Wilky, 2015, A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours, Br. J. Cancer, 112, 24, 10.1038/bjc.2014.515 · DOI
  120. Winter, 2015, Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activation, J. Med. Chem., 58, 2265, 10.1021/jm501660t · DOI · Paper page
  121. Xing, 2003, Pharmacologic inactivation of kinase suppressor of ras-1 abrogates Ras-mediated pancreatic cancer, Nat. Med., 9, 1266, 10.1038/nm927 · DOI
  122. Yu, 2015, The RAF-MEK-ERK pathway: targeting ERK to overcome obstacles to effective cancer therapy, Future Med. Chem., 7, 269, 10.4155/fmc.14.143 · DOI · Paper page
  123. Zhao, 2015, Rational combination of MEK inhibitor and the STAT3 pathway modulator for the therapy in K-Ras mutated pancreatic and colon cancer cells, Oncotarget, 6, 14472, 10.18632/oncotarget.3991 · DOI
  124. Zhu, 2012, PI3K expression and PIK3CA mutations are related to colorectal cancer metastases, World J. Gastroenterol., 18, 3745, 10.3748/wjg.v18.i28.3745 · DOI · Paper page
  125. Ziemke, 2016, Sensitivity of KRAS-Mutant colorectal cancers to combination therapy that cotargets MEK and CDK4/6, Clin. Cancer Res., 22, 405, 10.1158/1078-0432.CCR-15-0829 · DOI · Paper page

Cited by

See all 18

Metadata

Authors
Pant, S., Hubbard, J., Martinelli, E., & Bekaii-Saab, T.
Venue
Critical Reviews in Oncology/Hematology
Publisher
Elsevier BV
Published
2018-10
Volume
130
Pages
78-91
ISSN
1040-8428
Cited by
18
References
47
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Funders
  • Senhwa Biosciences, Inc
  • Boston Biomedical, Inc
  • Genentech, Taiho Pharmaceuticals
  • Merck. Dr. Hubbard

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical update on K-Ras targeted therapy in gastrointestinal cancers. https://app.cochat.ai/papers/10.1016/j.critrevonc.2018.07.011
The paper
Pant, S., Hubbard, J., Martinelli, E., & Bekaii-Saab, T. (2018). Clinical update on K-Ras targeted therapy in gastrointestinal cancers. Critical Reviews in Oncology/Hematology. https://doi.org/10.1016/j.critrevonc.2018.07.011

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.